Bayer confirms sale of animal health unit to Elanco for $7.6bnThe rumoured sale of Bayer’s animal health unit to Elanco has been confirmed as going ahead, with the Share XBayer confirms sale of animal health unit to Elanco for $7.6bnhttps://pharmaphorum.com/news/bayer-confirms-sale-of-animal-health-unit-to-elanco-for-7-6bn/
FDA approves Roche’s “tumour agnostic” drug RozlytrekThe FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in Share XFDA approves Roche’s “tumour agnostic” drug Rozlytrekhttps://pharmaphorum.com/news/fda-approves-roches-tumour-agnostic-drug-rozlytrek/
Bayer boosts cell therapy pipeline with BlueRock acquisitionBayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes Share XBayer boosts cell therapy pipeline with BlueRock acquisitionhttps://pharmaphorum.com/news/bayer-boosts-cell-therapy-pipeline-with-bluerock-acquisition/
NICE backs Bayer’s Xarelto in new stroke and heart attack prevention useBayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults Share XNICE backs Bayer’s Xarelto in new stroke and heart attack prevention usehttps://pharmaphorum.com/news/nice-backs-bayers-xarelto-in-new-stroke-and-heart-attack-prevention-use/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
FDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIBayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts Share XFDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIhttps://pharmaphorum.com/news/fda-clears-bayers-gadavist-as-first-contrast-agent-for-cardiac-mri/
Bayer may merge animal health unit with Elanco; reportBayer has delayed a planned sale of its animal health unit to private equity interests in order to Share XBayer may merge animal health unit with Elanco; reporthttps://pharmaphorum.com/news/bayer-may-merge-animal-health-unit-with-elanco-report/
Bayer/J&J eye new paediatric use for anticoagulant XareltoBayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving Share XBayer/J&J eye new paediatric use for anticoagulant Xareltohttps://pharmaphorum.com/news/bayer-jj-eye-new-paediatric-use-for-anticoagulant-xarelto/
Bayer begins phase 3 trial testing aflibercept in infant blindnessBayer has begun a late-stage trial of its blockbuster aflibercept eye drug to prevent blindness in premature infants. Share XBayer begins phase 3 trial testing aflibercept in infant blindnesshttps://pharmaphorum.com/news/bayer-begins-phase-3-trial-testing-aflibercept-in-infant-blindness/
